Coronavirus vaccine - Altimmune
Alternative Names: AdCOVID; Intranasal COVID-19 vaccine - AltimmuneLatest Information Update: 23 Aug 2023
At a glance
- Originator Altimmune
- Class COVID-19 vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued COVID 2019 infections
Most Recent Events
- 21 Dec 2022 Altimmune completes a phase I trial for COVID-2019 infections (Prevention) in USA (Intranasal) (NCT04679909)
- 29 Jun 2021 Immunogenicity and adverse event data from a phase I trial in COVID-2019 infections released by Altimmune
- 26 May 2021 Immunogenicity data from a preclinical trial in COVID-2019 infections released by Altimmune
Development Overview
Introduction
An intranasally administered coronavirus vaccine (COVID 19) was being developed by Altimmune for prevention against COVID-2019 infections. Altimmune is using its proprietary RespirVec platform to develop the candidate. AdCOVID is designed to stimulate a broad immune response including both systemic immunity (neutralizing antibody) and local immunity (mucosal IgA and resident memory T cells) in the nasal cavity and respiratory tract. The RespirVec platform is comprised of intranasal delivery of replication-deficient adenoviruses. The adenovectored pathogen sequences elicits a rapid as well as long-term immune protection. The technology includes intracellular expression of the vaccine antigen for authentic immune presentation, mobilisation of the innate, cellular and mucosal immune systems instead of just the antibody-based response triggered by conventional injectable vaccines, a more durable antibody response, self-adjuvanting adenovector delivery system with the potential to improve immunogenicity. The adenovirus type 5 (Ad5)-vectored vaccine encoding the receptor binding domain (RBD) of the SARS-CoV-2 spike protein, elicits a strong and focused systemic immune response against RBD through the induction of mucosal IgA, serum neutralizing antibodies and CD4+ and CD8+ T cells with a Th1-like cytokine expression profile. Clinical development was underway in the US. However as of June 2021, Altimmune discontinued development of its intranasally administered coronavirus vaccine due to lower of expected immunogenicity observed in clinical trial.
The vaccine is expected to provide downstream protection against viral spread by stimulating mucosal and systemic antibodies (IgA and IgG), in addition to cell-mediated immunity. This stimulation in the nasal cavity equips the vaccine to provide protection against the infection and its imminent dissemination. The intranasal route is expected to provide easier delivery as opposed to conventional injections. Also, the vaccine is supposed to possess extended stability at room temperature.
Altimmune is actively seeking partners for the development of intranasal coronavirus vaccine (Altimmune pipeline, March 2020).
Company Agreements
In March 2021, Altimmune entered into a agreement with Summit Biosciences to manufacture a metered nasal spray presentation for its coronavirus vaccine (AdCOVID). The financial terms of agreement remains undisclosed. [1]
In March 2021, Altimmune entered into a manufacturing agreement with Lonza for the manufacturing suite for clinical and commercial production of AdCOVID vaccine candidate. The terms of agreement remains undisclosed. [2]
As of February 2021, Altimmune entered an agreement with three commercial manufacturing partners for adenoviral vector production. The Company has also established relationships with leading drug product fill/finish partners to meet potential commercial demand. [3]
In March 2020, Altimmune entered into an agreement with University of Alabama at Birmingham (UAB) for the development of intranasal COVID-19 vaccine, AdCOVID. Under the terms of agreement, initially Altimmune will work with UAB investigators to perform preclinical studies and to analyse the vaccine immunogenicity. In third quarter of 2020, Altimmune and UAB expanded their collaboration to include additional preclinical studies to support further development. [4] [5]
Altimmune and Saint Louis University entered into a sponsored research agreement with Dr. James Brien at Saint Louis University (SLU) to conduct animal models of vaccine immunogenicity and efficacy. [5]
In July 2020, Altimmune and Vigene Biosciences entered in a manufacturing agreement for AdCOVID™. Further terms of the agreement were not disclosed by the companies. [6]
In July 2020, Altimmune forged a teaming agreement with DynPort Vaccine Company (DVC), to facilitate alignment with the US Government, for attracting prospective funding for the continued development of the former's coronavirus vaccine (AdCOVID™). Should these funding efforts meet with considerable success, DVC will also attempt co-ordination toward provision of further programme management, drug development activity integration and regulatory support in vaccine development. [7]
Key Development Milestones
In June 2021, Altimmune discontinued further development of AdCOVID, based on the data that demonstrated lower than expected immune responses for each of the immune parameters tested [8] [9] .
In December 2022, Altimmune completed a phase I trial (COVID-19 Vaccine Study) that investigated safety and immunogenicity of intranasal coronavirus vaccine (AdCOVID), healthy adult volunteers between the ages of 18 and 55 (NCT04679909; ALT-501-101). The immunogenicity of vaccine was evaluated by serum IgG binding and neutralising antibody titers, mucosal IgA antibody from nasal samples, and T cell responses. The double-blind, randomized, placebo-controlled trial was initiated in February 2021 and enrolled 92 healthy volunteers in the US [10] [11] . Later in same month company announced initiation of the enrollment in the trial [3] . In May 2021, Altimmune announced that the study protocol was amended to reduce the number of adult subjects to approximately 80 participants and the company also reported that the enrolment target was met [12] . In June 2021, Altimmune released safety and immunogenicity data from a trial. Based on the data that demonstrated lower than expected immune responses for each of the immune parameters tested, Altimmune will discontinue further development of AdCOVID beyond the completion of this phase I trial [9] .
In February 2021, Altimmune announced that the US FDA has cleared the Investigational New Drug (IND) application for its phase I clinical trial [see above] of intranasal coronavirus vaccine (AdCOVID), for the prevention of COVID-2019 infections [13] . In December 2020, Altimmune announced that the US FDA had issued a clinical hold letter on the IND application for the vaccine. The US FDA requested certain protocol modifications and the submission of additional Chemistry, Manufacturing and Controls (CMC) data. Altimmune had responded by agreeing to each of the US FDA’s requests and does not anticipate significant impact on clinical development timeline [14] . Earlier, in November 2020, Altimmune submitted an IND to the US FDA to initiate a phase I trial of its intranasal COVID-19 vaccine. The IND included a preliminary proposal for evaluation of children as young as 2 years of age, and the company announced its plan to further discussions around our pediatric program with the US FDA in the near future. In a recent pre-IND meeting, the US FDA agreed to the overall phase I study design and patient population, as well as plans for manufacturing and product testing of the vaccine. The US FDA also confirmed that additional nonclinical studies were not required before the initiation of the phase I trial. The toxicology data previously submitted and reviewed for Altimmune’s NasoShield™ and NasoVAX™ intranasal vaccine candidates support the clinical development of the coronavirus vaccine, with no additional toxicology studies required [15] .
In September 2020, Altimmune reported that it plans on submitting an investigational new drug application (IND) with the US FDA and subsequently initiate a phase I trial in fourth quarter of 2020 [16] .
In May 2021, Altimmune initiated a preclinical study for the evaluation of coronavirus (AdCOVID) vaccine candidates targeting E484K variants, including P.1, B.1.351 and B.1.617. The company announced new results from the demonstrating the ability of its AdCOVID vaccine candidate to neutralise the rapidly emerging SARS-CoV-2 B.1.351 variant that originated in South Africa [17] [12] .
As of May 2020, Altimmune in collaboration with the University of Alabama at Birmingham (UAB) initiated preclinical testing of COVID-19 vaccine [18] . In July 2020, the company released the preclinical data [19] . In August 2020, additional results from preclinical studies were released by Altimmune and the University of Alabama, which demonstrated that the COVID-19 vaccine specifically stimulates three key components of the immune system which are serum neutralizing antibody, T-cell responses, and mucosal immunity in the respiratory tract. The mucosal immunity was characterized by IgA antibody and resident memory T cell responses in the respiratory tract [20] [21] [22] . In March 2021, Altimmune announced additional preclinical data for its single dose intranasal coronavirus vaccine (AdCOVID) [23] .
In May 2021, Altimmune released immunogenicity data from a preclinical study in COVID-2019 infections [24] .
As of February 2020, the design and synthesis of the vaccine was completed. Altimmune announced its intention to advance it towards animal testing and manufacturing [25] .
Financing information
In July 2020, Altimmune reported the pricing of its previously announced public offering, comprised of common stock and pre-funded warrants to certain investors for purchasing additional shares of its common stock. Altimmune also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of common stock plus the shares of common stock underlying the pre-funded warrants sold in connection with the public offering. The offering is expected to yield gross proceeds of approximately $US132.2 and pre-funded warrants, $US40.9 million from warrant exercises and $US26.3 million in gross proceeds from ATM sales million. Net proceeds are slated to be utilised for general corporate purposes, scale up of manufacturing and advanced clinical trials of coronavirus vaccine (AdCOVID™), the continued development of ALT 801 [see AdisInsight drug profile 800037378] including manufacturing and clinical trials, and for capital expenditures and working capital [26] [27] [28] [29] .
Patent Information
AdCOVID is covered by patent rights related to RespirVec platform technology, for which patent applications are pending in the US, Europe and Japan. The claims are directed to a method of inducing an innate immune response against coronavirus following intranasal administration of an effective amount of E1 and/or E3 deleted adenovirus expressing a coronavirus antigen. The patent application(s), if issued, would have an expiration date no earlier than March 2032, not giving effect to any potential extensions and assuming payment of all associated fees. Altimmune plans to file an international (PCT) patent application followed by national and regional applications for the use and dosing of AdCOVID in the U.S., Europe and other commercially jurisdictions [30] .
Altimmune has a patent application filed for replication-deficient adenoviral vectored RespirVec platform technology in the US, Taiwan, Argentina and an international (PCT) patent application filed in other commercial jurisdictions like Europe and Japan [30] .
Drug Properties & Chemical Synopsis
- Route of administration Intranasal
- Formulation Spray
- Class COVID-19 vaccines, Viral vaccines
- Mechanism of Action Immunostimulants
-
WHO ATC code
J07B-X (Other viral vaccines)
-
EPhMRA code
J7E9 (All other viral vaccines)
Biomarkers Sourced From Trials
| Indication | Biomarker Function | Biomarker Name | Number of Trials |
|---|---|---|---|
|
cOVID 2019 infections |
Outcome Measure |
Interferon Gamma (IFNg) |
Biomarker
| Drug Name | Biomarker Name | Biomarker Function |
|---|---|---|
| Coronavirus vaccine - Altimmune | Interferon Gamma (IFNg) | Outcome Measure |
Development Status
Summary Table
| Indication | Qualifier | Patient Segment | Phase | Countries | Route / Formulation | Developers | Event Date |
|---|---|---|---|---|---|---|---|
| COVID 2019 infections | - | Prevention | Discontinued (I) | USA | Intranasal / Spray | Altimmune | 29 Jun 2021 |
Commercial Information
Involved Organisations
| Organisation | Involvement | Countries |
|---|---|---|
| Altimmune | Originator | USA |
| Altimmune | Owner | USA |
| Summit Biosciences | Collaborator | USA |
| DynPort Vaccine Company | Collaborator | USA |
| Lonza | Collaborator | Switzerland |
| University of Alabama at Birmingham | Collaborator | USA |
| Saint Louis University | Collaborator | USA |
Licensing Availability
| Licensing Organisation | Available Indication | Available Phase | Region | Date |
|---|---|---|---|---|
| Altimmune | - | Unspecified | - | 05 Mar 2020 |
Brand Names
| Brand Name | Organisations | Indications | Countries |
|---|---|---|---|
| AdCOVID | Altimmune | COVID 2019 infections | USA |
Scientific Summary
Adverse Events
Immunogenicity
Summary
In preclinical studies AdCOVID vaccine candidate neutralised the rapidly emerging SARS-CoV-2 B.1.351 variant that originated in South Africa. The neutralising titer against the B.1.351 variant virus was 4.4-fold lower than the neutralising titer against an original or ancestral Wuhan-like isolate when measured seven weeks after a single intranasal dose of AdCOVID. In mice that received a booster dose of AdCOVID, the reduction in the neutralising titer against the B.1.351 variant was only 1.8-fold lower at seven weeks post vaccination, statistically same as the neutralisation titer against the Wuhan isolate. AdCOVID promoted a strong mucosal neutralising response to the B.1.351 virus in the respiratory tract with bronchoalveolar lavages showing neutralisation of the variant virus [17]
In preclinical studies, single intranasal dose of coronavirus vaccine (AdCOVID) demonstrated 100% protection against a lethal challenge from the SARS-CoV-2 virus in the K18-hACE2 transgenic mouse model. All animals that received AdCOVID survived and had no observed weight loss. Initial immunogenicity analysis showed mean antibody levels of about 1 mg/mL, suggesting that the serum IgG antibody response against the spike protein was robust. A single intranasal dose of AdCOVID resulted in a greater than 1000-fold reduction in replicating virus in the nasal cavity and respiratory tract following infection with SARS-CoV-2 virus. Moreover, it also demonstrated that serum IgG and respiratory mucosal IgA titers in mice treated with AdCOVID were maintained for at least 6 months following a single intranasal vaccination and that memory B cells specific for spike antigen were found in the lymph nodes when assessed 5.5 months post-vaccination [23] . In preclinical studies, coronavirus vaccine (AdCOVID) elicited a strong systemic antibody response against receptor binding domain (RBD) in two murine models, and achieved serum IgG antibody concentrations greater than 800 micrograms per milliliter just 14 days after administration of a single intranasal dose. AdCOVID stimulated serum viral neutralization titers of 1:320 by day 28. One-month post-vaccination, AdCOVID elicited a median serum neutralization titer of up to 1:563 against wild-type SARS-CoV-2 virus, in a 50% focus reduction neutralization test (FRNT). This neutralisation activity is at least 3-times more than the minimum titer recommended by the US FDA for convalescent plasma treatment of COVID-19 infections. In a separate study, a single intranasal dose of AdCOVID stimulated a 29-fold induction of mucosal IgA in bronchoalveolar fluid of vaccinated mice. This level of IgA antibody stimulation is well above the 2 to 4-fold increase in IgA that is associated with protection from disease in clinical studies of other mucosal vaccines. In preclinical studies, vaccination with AdCOVID caused the rapid recruitment of immune cells into the respiratory tract and draining lymph nodes consistent with induction of mucosal and systemic immunity. Increase in CD8+ and CD4+ T cells, dendritic cells and NK cells were observed in the respiratory tract, and germinal center and memory B cells as well as T follicular helper cells were observed in regional lymph nodes and the spleen. The latter cell types have been associated in prior vaccine development research with long-lived antibody responses. Additional results demonstrated potent stimulation of antigen-specific CD4+ and CD8+ T cells in the lungs of CD-1 mice as early as 10 days following a single intranasal vaccination, with responses strongly biased toward CD8+ T cells. Both CD4+ and CD8+ T cells displayed phenotypes consistent with the Th1 type immune response that is important for control of viral infections. The mean serum neutralisation titers 4-weeks after a single intranasal dose exceeded 1:400 in a foci reduction neutralisation assay against wild-type SARS-CoV-2 virus [20] [21] [19] [22] .
In preclinical study, administration of AdCOVID reported no levels of infectious virus in the lungs of vaccinated mice, with a one million-fold reduction of infectious virus. Further a high serum neutralizing antibody and T cell responses, with mucosal IgA responses reported in the respiratory tract [24] .
In a phase I trial (COVID-19 Vaccine Study), intranasal coronavirus vaccine (AdCOVID) demonstrated lower than expected immune responses for each of the immune parameters tested. Although antibodies were detected that bound the SARS-CoV-2 Spike protein and neutralized the virus in a subset of participants, the magnitude of the response and the percent of participants responding to AdCOVID were substantially lower than what had been demonstrated for other vaccines already authorized for emergency use [9] [11] .
Future Events
| Expected Date | Event Type | Description | Updated |
|---|---|---|---|
| 28 Feb 2021 | Trial Update | Altimmune plans a phase I trial for COVID-2019 infections (Prevention) (Intranasal) in February 2021 (NCT04679909) (700320289) [13] | 01 Mar 2021 |
| 31 Dec 2020 | Regulatory Status | Altimmune plans to submit IND with the US FDA for COVID-2019 infections (Prevention) in Q4 2020 [16] | 19 Feb 2021 |
| 30 Sep 2020 | Trial Update | Altimmune plans to initiate manufacturing of its coronavirus vaccine for COVID-2019 infections (Prevention) (Intranasal) in the third quarter of 2020 [7] | 14 Jul 2020 |
| 30 Jun 2020 | Trial Update | Altimmune plans preclinical studies in the second quarter of 2020 [31] | 14 Jul 2020 |
Development History
| Event Date | Update Type | Comment |
|---|---|---|
| 21 Dec 2022 | Trial Update | Altimmune completes a phase I trial for COVID-2019 infections (Prevention) in USA (Intranasal) (NCT04679909) Updated 23 Aug 2023 |
| 15 Jul 2021 | Biomarker Update | Biomarkers information updated Updated 02 Oct 2021 |
| 29 Jun 2021 | Phase Change - Discontinued(I) | Discontinued - Phase-I for COVID-2019 infections (Prevention) in USA (Intranasal), due to lower than expected immunogenicity in clinical trial [8] Updated 22 Apr 2022 |
| 29 Jun 2021 | Scientific Update | Immunogenicity and adverse event data from a phase I trial in COVID-2019 infections released by Altimmune [9] Updated 07 Jul 2021 |
| 26 May 2021 | Scientific Update | Immunogenicity data from a preclinical trial in COVID-2019 infections released by Altimmune [17] Updated 31 May 2021 |
| 17 May 2021 | Trial Update | Altimmune plans a phase II trial for COVID-2019 infections (Prevention, In children, In adolescents, In adults) (Intranasal, Spray), in the fourth quarter of 2021 [12] Updated 22 Apr 2022 |
| 17 May 2021 | Trial Update | Altimmune completes enrolment in its phase I trial for COVID-2019 infections (Prevention) in USA (Intranasal) (NCT04679909) [12] Updated 22 May 2021 |
| 17 May 2021 | Trial Update | Altimmune initiates a preclinical trial for COVID-2019 infections (Prevention) in USA [12] Updated 22 May 2021 |
| 10 May 2021 | Scientific Update | Immunogenicity data from a preclinical study in COVID-2019 infections released by Altimmune [24] Updated 16 May 2021 |
| 22 Mar 2021 | Licensing Status | Altimmune and Summit Biosciences enter into an agreement to produce a multidose nasal spray presentation for coronavirus vaccine [1] Updated 31 May 2021 |
| 15 Mar 2021 | Scientific Update | Immunogenicity data from a preclinical trial in COVID-2019 infections released by Altimmune [23] Updated 17 Mar 2021 |
| 12 Mar 2021 | Licensing Status | Altimmune and Lonza enter into a manufacturing agreement for coronavirus vaccine [2] Updated 18 Mar 2021 |
| 25 Feb 2021 | Phase Change - I | Phase-I clinical trials in COVID-2019 infections (Prevention) in USA (Intranasal) (NCT04679909) [10] Updated 01 Mar 2021 |
| 17 Feb 2021 | Trial Update | Altimmune plans a phase I trial for COVID-2019 infections (Prevention) (Intranasal) in February 2021 (NCT04679909) [13] Updated 01 Mar 2021 |
| 17 Feb 2021 | Regulatory Status | US FDA clears IND application for coronavirus vaccine in COVID-2019 infections (Prevention) [13] Updated 19 Feb 2021 |
| 31 Dec 2020 | Patent Information | Altimmune has patents pending for AdCOVID in the US, Europe and Japan [30] Updated 27 Jun 2021 |
| 31 Dec 2020 | Patent Information | Altimmune has patents pending for replication-deficient adenoviral vectored RespirVec platform technology in the US, Taiwan, Argentina, Europe and Japan [30] Updated 27 Jun 2021 |
| 31 Dec 2020 | Patent Information | Altimmune has international patents pending for Use and dosing of AdCOVID [30] Updated 27 Jun 2021 |
| 24 Dec 2020 | Regulatory Status | The US FDA issued clinical hold letter on IND application for COVID-2019 infections [14] Updated 29 Dec 2020 |
| 25 Nov 2020 | Regulatory Status | Altimmune announces intention to discuss the paediatric programme with the US FDA [15] Updated 30 Nov 2020 |
| 25 Nov 2020 | Regulatory Status | Altimmune files an IND application with the US FDA in COVID-2019 infections [15] Updated 30 Nov 2020 |
| 09 Nov 2020 | Licensing Status | Altimmune and Saint Louis University enter into a sponsored research agreement for coronavirus vaccine [5] Updated 17 Nov 2020 |
| 09 Nov 2020 | Licensing Status | Altimmune and the University of Alabama at Birmingham expanded their agreement [5] Updated 17 Nov 2020 |
| 12 Oct 2020 | Scientific Update | Updated immunogenicity data from preclinical studies in COVID-2019 infections released by Altimmune and University of Alabama [20] Updated 14 Oct 2020 |
| 28 Sep 2020 | Regulatory Status | Altimmune plans to submit IND with the US FDA for COVID-2019 infections (Prevention) in Q4 2020 [16] Updated 19 Feb 2021 |
| 25 Aug 2020 | Scientific Update | Additional immunogenicity data from preclinical studies in COVID-2019 infections released by Altimmune and the University of Alabama [22] Updated 27 Aug 2020 |
| 13 Jul 2020 | Scientific Update | Immunogenicity data from preclinical studies in COVID-2019 infections released by Altimmune [19] Updated 16 Jul 2020 |
| 09 Jul 2020 | Licensing Status | Altimmune signs Teaming Agreement with DynPort Vaccine Company to attract US Government funding for development in COVID-2019 infections (Prevention) (Intranasal) [7] Updated 14 Jul 2020 |
| 09 Jul 2020 | Trial Update | Altimmune plans to initiate manufacturing of its coronavirus vaccine for COVID-2019 infections (Prevention) (Intranasal) in the third quarter of 2020 [7] Updated 14 Jul 2020 |
| 13 May 2020 | Phase Change - Preclinical | Preclinical trials in COVID-2019 infections (Prevention) in USA (Intranasal) before May 2019 [18] Updated 19 May 2020 |
| 30 Mar 2020 | Licensing Status | Altimmune and University of Alabama at Birmingham signs research and development agreement for coronavirus vaccine [4] Updated 06 Apr 2020 |
| 27 Mar 2020 | Trial Update | Altimmune plans preclinical studies in the second quarter of 2020 [31] Updated 14 Jul 2020 |
| 05 Mar 2020 | Licensing Status | Coronavirus vaccine - is available for licensing as of 05 Mar 2020. https://altimmune.com/about-us/ Updated 05 Mar 2020 |
| 05 Mar 2020 | Trial Update | Altimmune plans preclinical studies for COVID-2019 infections (Prevention) [25] Updated 05 Mar 2020 |
| 28 Feb 2020 | Phase Change | Early research in COVID-2019 infections (Prevention) in USA (Intranasal) [25] Updated 05 Mar 2020 |
References
-
Altimmune Partners with Summit Biosciences to Produce a Multidose Nasal Spray Presentation of its AdCOVID(Tm) Vaccine Candidate.
Media Release -
Altimmune Expands AdCOVID(Tm) Manufacturing Collaboration with Lonza.
Media Release -
Altimmune Announces Financial Results for the Year Ended December 31, 2020 and Provides a Corporate Update.
Media Release -
Altimmune and the University of Alabama at Birmingham to Collaborate on Development of Single-Dose, Intranasal COVID-19 Vaccine.
Media Release -
Altimmune Announces Third Quarter 2020 Financial Results and Provides a Business Update.
Media Release -
Altimmune Announces Manufacturing Agreement with Vigene Biosciences for AdCOVID(Tm), its Single Dose Intranasal Vaccine Candidate for COVID-19.
Media Release -
Altimmune Signs Teaming Agreement with DynPort Vaccine Company on U.S. Government Funding Efforts for its COVID-19 Vaccine Candidate, AdCOVID(Tm).
Media Release -
Altimmune Form 10-K, December 2021. Internet-Doc 2022;.
Available from: URL: https://www.sec.gov/ix?doc=/Archives/edgar/data/1326190/000155837022003659/alt-20211231x10k.htm -
Altimmune Announces Update on AdCOVID(Tm) Phase 1 Clinical Trial.
Media Release -
Altimmune Commences Enrollment in Phase 1 Clinical Trial of AdCOVID(Tm) -- a Needle-Free, Single-Dose Intranasal COVID-19 Vaccine Candidate.
Media Release -
A Phase 1, Double-blind, Randomized, Placebo-controlled, First-in-Human Study of the Safety and Immunogenicity of AdCOVID Administered as One or Two Doses
ctiprofile -
Altimmune Announces First Quarter 2021 Financial Results and Provides a Corporate Update.
Media Release -
Altimmune Announces FDA Clearance of AdCOVID(Tm) IND Application.
Media Release -
Altimmune Provides an Update on its Investigational New Drug Application for a Phase 1 AdCOVID(Tm) Clinical Trial.
Media Release -
Altimmune Announces Submission of Investigational New Drug Application for AdCOVID(Tm) a Single-dose Intranasal COVID-19 Vaccine; On Track to Commence Phase 1 Clinical Study in December.
Media Release -
Altimmune Presents Highlights of Intranasal COVID-19 Vaccine and Therapeutic Programs AdCOVID(Tm) and T-COVID(Tm) at the World Vaccine Congress.
Media Release -
Altimmune Demonstrates Strong Neutralization of South African Variant in Preclinical Study of Intranasal AdCOVID(Tm).
Media Release -
Altimmune Announces First Quarter 2020 Financial Results and Provides a Business Update.
Media Release -
Altimmune and the University of Alabama at Birmingham (UAB) Announce Positive Preclinical Results for Intranasal COVID-19 Vaccine Candidate, AdCOVID(Tm).
Media Release -
Altimmune and UAB Announce Publication of Compelling Pre-clinical Data for AdCOVID(Tm) Intranasal COVID-19 Vaccine Candidate.
Media Release -
Single-dose intranasal administration of AdCOVID elicits systemic and mucosal immunity against SARS-CoV-2 in mice. Internet-Doc 2020;.
Available from: URL: https://www.biorxiv.org/content/10.1101/2020.10.10.331348v1.full -
Altimmune and the University of Alabama at Birmingham Announce Potent Respiratory Mucosal T Cell Responses in Preclinical Study of Single-Dose Intranasal COVID-19 Vaccine Candidate, AdCOVID(Tm).
Media Release -
AdCOVID(Tm), Altimmunes Single Dose, Intranasal COVID-19 Vaccine Candidate, Prevents SARS-CoV-2-induced Disease and Blocks Viral Replication in Preclinical Studies of SARS-CoV-2 Infection.
Media Release -
Altimmune Announces New Preclinical Data for AdCOVID(Tm) Demonstrating Sterilizing Immunity After a Single Intranasal Dose.
Media Release -
Altimmune Completes First Development Milestone Toward a Single-Dose Intranasal COVID-19 Vaccine.
Media Release -
Altimmune Announces Second Quarter 2020 Financial Results and Provides a Business Update.
Media Release -
Altimmune Announces Pricing of a Public Offering of $115 Million of Common Stock and Pre-Funded Warrants.
Media Release -
Altimmune Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants.
Media Release -
Altimmune Announces Closing of $132 Million Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters Option.
Media Release -
ALTIMMUNE - FORM 10K December 2020. Internet-Doc 2021;.
Available from: URL: https://www.sec.gov/Archives/edgar/data/1326190/000156459021008422/alt-10k_20201231.htm -
Altimmune Announces Financial Results for the Year Ended December 31, 2019 and Provides a Corporate Update.
Media Release
Adis International Ltd. Part of Springer Science+Business Media
© Springer Nature Switzerland AG